197 related articles for article (PubMed ID: 20406486)
1. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
Søndergaard JN; Nazarian R; Wang Q; Guo D; Hsueh T; Mok S; Sazegar H; MacConaill LE; Barretina JG; Kehoe SM; Attar N; von Euw E; Zuckerman JE; Chmielowski B; Comin-Anduix B; Koya RC; Mischel PS; Lo RS; Ribas A
J Transl Med; 2010 Apr; 8():39. PubMed ID: 20406486
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N
Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863
[TBL] [Abstract][Full Text] [Related]
3. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP
Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Roller DG; Capaldo B; Bekiranov S; Mackey AJ; Conaway MR; Petricoin EF; Gioeli D; Weber MJ
Oncotarget; 2016 Jan; 7(3):2734-53. PubMed ID: 26673621
[TBL] [Abstract][Full Text] [Related]
5. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Straussman R; Morikawa T; Shee K; Barzily-Rokni M; Qian ZR; Du J; Davis A; Mongare MM; Gould J; Frederick DT; Cooper ZA; Chapman PB; Solit DB; Ribas A; Lo RS; Flaherty KT; Ogino S; Wargo JA; Golub TR
Nature; 2012 Jul; 487(7408):500-4. PubMed ID: 22763439
[TBL] [Abstract][Full Text] [Related]
6. Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity.
Pich C; Teiti I; Sarrabayrouse G; Gallardo F; Gence R; Tilkin-Mariamé AF
PLoS One; 2016; 11(2):e0148095. PubMed ID: 26828592
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal.
Lu Y; Zhao Y; Liu P; Xu X
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37643458
[TBL] [Abstract][Full Text] [Related]
8. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Marsh Durban V; Deuker MM; Bosenberg MW; Phillips W; McMahon M
J Clin Invest; 2013 Dec; 123(12):5104-18. PubMed ID: 24200692
[TBL] [Abstract][Full Text] [Related]
9. Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases.
Seifert H; Hirata E; Gore M; Khabra K; Messiou C; Larkin J; Sahai E
Pigment Cell Melanoma Res; 2016 Jan; 29(1):92-100. PubMed ID: 26414886
[TBL] [Abstract][Full Text] [Related]
10. Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
Porcelli L; Guida G; Quatrale AE; Cocco T; Sidella L; Maida I; Iacobazzi RM; Ferretta A; Stolfa DA; Strippoli S; Guida S; Tommasi S; Guida M; Azzariti A
J Transl Med; 2015 Jan; 13():26. PubMed ID: 25623468
[TBL] [Abstract][Full Text] [Related]
11. Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma.
Zecena H; Tveit D; Wang Z; Farhat A; Panchal P; Liu J; Singh SJ; Sanghera A; Bainiwal A; Teo SY; Meyskens FL; Liu-Smith F; Filipp FV
BMC Syst Biol; 2018 Apr; 12(1):33. PubMed ID: 29615030
[TBL] [Abstract][Full Text] [Related]
12. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
Ohanna M; Cerezo M; Nottet N; Bille K; Didier R; Beranger G; Mograbi B; Rocchi S; Yvan-Charvet L; Ballotti R; Bertolotto C
Genes Dev; 2018 Mar; 32(5-6):448-461. PubMed ID: 29567766
[TBL] [Abstract][Full Text] [Related]
13. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.
Smalley I; Kim E; Li J; Spence P; Wyatt CJ; Eroglu Z; Sondak VK; Messina JL; Babacan NA; Maria-Engler SS; De Armas L; Williams SL; Gatenby RA; Chen YA; Anderson ARA; Smalley KSM
EBioMedicine; 2019 Oct; 48():178-190. PubMed ID: 31594749
[TBL] [Abstract][Full Text] [Related]
14. RAC1
Lionarons DA; Hancock DC; Rana S; East P; Moore C; Murillo MM; Carvalho J; Spencer-Dene B; Herbert E; Stamp G; Damry D; Calado DP; Rosewell I; Fritsch R; Neubig RR; Molina-Arcas M; Downward J
Cancer Cell; 2019 Jul; 36(1):68-83.e9. PubMed ID: 31257073
[TBL] [Abstract][Full Text] [Related]
15. Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.
Song K; Minami JK; Huang A; Dehkordi SR; Lomeli SH; Luebeck J; Goodman MH; Moriceau G; Krijgsman O; Dharanipragada P; Ridgley T; Crosson WP; Salazar J; Pazol E; Karin G; Jayaraman R; Balanis NG; Alhani S; Sheu K; Ten Hoeve J; Palermo A; Motika SE; Senaratne TN; Paraiso KH; Hergenrother PJ; Rao PN; Multani AS; Peeper DS; Bafna V; Lo RS; Graeber TG
Cancer Discov; 2022 Apr; 12(4):1046-1069. PubMed ID: 34930786
[TBL] [Abstract][Full Text] [Related]
16. PEG-peptide hydrogels reveal differential effects of matrix microenvironmental cues on melanoma drug sensitivity.
Tokuda EY; Jones CE; Anseth KS
Integr Biol (Camb); 2017 Jan; 9(1):76-87. PubMed ID: 28001152
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the Human Kinome and Phosphatome by Mass Cytometry Reveals Overexpression-Induced Effects on Cancer-Related Signaling.
Lun XK; Szklarczyk D; Gábor A; Dobberstein N; Zanotelli VRT; Saez-Rodriguez J; von Mering C; Bodenmiller B
Mol Cell; 2019 Jun; 74(5):1086-1102.e5. PubMed ID: 31101498
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic profiling of Raf inhibitors and mitochondrial toxicity in 3D tissue using biodynamic imaging.
An R; Merrill D; Avramova L; Sturgis J; Tsiper M; Robinson JP; Turek J; Nolte DD
J Biomol Screen; 2014 Apr; 19(4):526-37. PubMed ID: 24361645
[TBL] [Abstract][Full Text] [Related]
19. A Series of BRAF- and NRAS-Driven Murine Melanoma Cell Lines with Inducible Gene Modulation Capabilities.
Bok I; Angarita A; Douglass SM; Weeraratna AT; Karreth FA
JID Innov; 2022 Mar; 2(2):100076. PubMed ID: 35146482
[TBL] [Abstract][Full Text] [Related]
20. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
